Targeting remyelination treatment for multiple sclerosis

Table 1 Known pathways affecting remyelination in multiple sclerosis

Pathway	Potential protein targets	Drugs	Ref.
Hyaluronan	TLR2	TLR2 Ab (OPN-305)	[28]
	Hyaluronidase	Vcpal	[28,30]
Notch-1	Notch-1	(pan) BMS-906024	[14,15,17,19]
	Jagged-1	-	[14]
	Endothelin-1	PD142,893, sitaxentan, ambrisentan, atrasentan, BQ-123, zibotentan, bosentan, macitentan, tezosentan	[17]
	γ-secretase	MW167, LY450139	[93]
Retinoid X receptor	RXR-γ	Bexarotene, IRX4204	[31]
Wnt/ß-catenin	ß-catenin	PKF118-744, CGP049090, PKF118-310, XTM000990, BC21, PKF115-584, PNU-74654	[21,22]
	Tankyrases 1-2	XAV939, IWR1, JW74, JW55	[57]
	GSK3ß	SB216763	[20]
LINGO-1	LINGO-1	Anti-LINGO-1 Ab	[23-25]
CXCL12/CXCR4	CXCR7	CCX771	[37,38]
	CXCR4	AMD3100	[37,38]
GPR17	GPR17	Unnamed	Omeros

TLR2: Toll-like-receptor 2; GPR17: G protein-coupled receptor 17; CXCL4: C-X-C chemokine receptor type 4; CXCL12: Chemokine (C-X-C Motif) ligand 12.